Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A - Kruse-Jarres, R.; St-Louis, J.; Greist, A.; Shapiro, A.; Smith, H.; Chowdary, P.; Drebes, A.; Gomperts, E.; Bourgeois, C.; Mo, M.; Novack, A.; Farin, H.; et al. (Haemophilia : the official journal of the World Federation of Hemophilia, 2015)
Keywords: acquired haemophilia A; Adult; Aged; Aged, 80 and over; Animals; Antibodies, Neutralizing; Autoantibodies; Autoantibodies - immunology; Bleeding; bleeding episodes; Coagulation factors; Cross Reactions - immunology; Dosage; Factor VIII - administration & dosage; Factor VIII - adverse effects; Factor VIII - immunology; Factor VIII - therapeutic use; Female; Hemophilia; Hemophilia A - drug therapy; Hemophilia A - immunology; Humans; Hypersensitivity; Male; Middle Aged; recombinant FVIII porcine sequence; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - immunology; Recombinant Proteins - therapeutic use; replacement therapy; Swine; Thrombocytopenia; Time Factors; Treatment Outcome; acquired haemophilia A; bleeding episodes; recombinant FVIII porcine sequence; replacement therapy